Search

Your search keyword '"Pechlaner, C"' showing total 187 results
Start Over Author "Pechlaner, C"
187 results on '"Pechlaner, C"'

11. Ineffective off-label use of recombinant activated factor VII in a case of bone-marrow transplantation-related gastrointestinal bleeding

Author

Wiedermann CJ, Pechlaner C, and Eller P

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Abstract Background For patients with a normal coagulation system, who experience serious bleeding, sound evidence for recombinant activated factor VII (rFVIIa) as an effective haemostatic agent is only scarcely available so far from controlled clinical trials. In systematic reviews on the clinical use of rFVIIa, treatment failures were only rarely reported. Case presentation We present a 45-year old, Caucasian male with persistent intestinal bleeding due to enterocolitis associated with cytomegalovirus infection and acute graft-versus-host-disease. He had received allogeneic peripheral blood stem cell transplantation from an unrelated HLA-identical donor because of chronic myelogenous leukaemia diagnosed two years earlier. Bleeding started at day 18 after transplantation with bloody diarrhea, which was treated with multiple transfusions of fresh frozen plasma, platelet, and red blood cell concentrates, and continued relentlessly, despite all efforts, including continued transfusions, high-dose prednisolone, broad antibiotic and antiviral coverage, and tranexamic acid. Recombinant FVIIa was started at boluses of 90–120 μg/kg every 4–8 hours. Despite more than 10 doses, recurrent severe bleeding progressed to refractory shock, multiorgan failure and death. Conclusions Little can be concluded from single case reports of clinical improvement, because publication bias in favour of positive effects is likely. Our case suggests that rFVIIa is not a panacea, in particular for severe bleeding after bone-marrow transplantation. As long as rigorous, controlled studies or comprehensive registries are lacking, conventional interventions remain the standard of care in non-haemophilic patients with severe bleeding.

Published
2006
Full Text
View/download PDF

14. Role of thrombolysis in resuscitation

Author

Sheridan, P J, Chan, K H, Ray, K K, Baubin, M, Kroesen, G, Lichtenberger, C, Pechlaner, C, Lederer, W, Martin, Eike, Bode, Christoph, Motsch, Johann, Bauer, Harald, Bottiger, Bernd W, Jefferson, Heather J, Ho, Timothy B L, Coates, Lucy, and Harper, Adam

Subjects
Cardiac resuscitation -- Methods, CPR (First aid) -- Methods, Thrombolytic therapy -- Evaluation
Published
2001

15. Validation of CPOE systems by contextualized test cases: Report from a European Project

Author

Ammenwerth, E, Hackl, W, and Pechlaner, C

Subjects
validation, ddc: 610, eMedication, contextualized CDSS, test cases, 610 Medical sciences, Medicine, CPOE
Abstract

Introduction: Medication errors seem to be frequent in health care [ref:1]. Several reports recommend to implement electronic prescribing to reduce the number of medication errors [ref:2], [ref:3]. In the U.S., only 5% of hospitals have fully implemented computerized[for full text, please go to the a.m. URL], 54. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (gmds)

Published
2009
Full Text
View/download PDF

17. Septicaemia and endomyocarditis caused by Aerococcus urinae

Author

Gritsch W, Markus Nagl, Hausdorfer J, Gschwendtner A, Pechlaner C, and Cj, Wiedermann

Subjects
Adult, Male, Myocarditis, Fatal Outcome, Coronary Thrombosis, Sepsis, Streptococcaceae, Myocardial Infarction, Shock, Cardiogenic, Humans, Endocarditis, Bacterial, Coronary Vessels, Gram-Positive Bacterial Infections
Abstract

Aerococcus urinae, an uncommon urinary tract pathogen, was recently shown to cause septicaemia and endocarditis in a few patients in Denmark and the Netherlands. In Austria this is the first report of a fatal course of endomyocarditis by Aerococcus urinae, associated with multiple septic infarcts.

Published
1999

20. Factor XI and phosphorylase b kinase deficiency

Author

Yoon S. Shin, Daniela Skladal, Sölder B, Wolfgang Sperl, Kunz F, and Pechlaner C

Subjects
chemistry.chemical_classification, business.industry, Factor XI Deficiency, Phosphorylase Kinase, Infant, medicine.disease, Glycogen Storage Disease, Enzyme, Biochemistry, chemistry, Recien nacido, Genetics, Medicine, Glycogen storage disease, Humans, Female, Phosphorylase B Kinase Deficiency, Phosphorylase kinase, business, Factor XI, Genetics (clinical), Hepatomegaly
Published
1995

21. Dual source CT vs. Dual energy CT vs. konventionelles helikales CT: Vergleich zwischen Bildqualität und Strahlenbelastung von verschiedenen Protokollen zur Abklärung der Pulmonalembolie

Author

De Zordo, T, primary, Lutterotti, K von, additional, Dejaco, C, additional, Soegner, P, additional, Frank, R, additional, Klauser, A, additional, Pechlaner, C, additional, Aigner, F, additional, Girtler, MT, additional, Jaschke, W, additional, and Feuchtner, G, additional

Published
2011
Full Text
View/download PDF

28. Biventricular Pacing in Patients with Heart Failure

Author

Gritsch W and Pechlaner C

Subjects
medicine.medical_specialty, business.industry, medicine.drug_class, Deep vein, Low molecular weight heparin, General Medicine, medicine.disease, Gastroenterology, Thrombosis, medicine.anatomical_structure, Internal medicine, Medicine, In patient, business
Published
2001

30. A Funny Patient

Author

Sojer, M., primary, Eller, P., additional, Schmidauer, C., additional, and Pechlaner, C., additional

Published
2007
Full Text
View/download PDF

35. Diagnosing pulmonary embolism

Author

Holemans, J. A, primary, Reidy, J. F, additional, Borland, C., additional, Hawkins, P, additional, Pechlaner, C., additional, Buratti, T., additional, Wiedermann, C., additional, Fitzmaurice, D., additional, Murray, E T, additional, and Hobbs, F D R, additional

Published
1997
Full Text
View/download PDF

41. The CHARM programme.

Author

Pechlaner C, Gama MG, Rocha G, Mansour J, Peltier M, Oprisiu R, Achard JM, Fournier A, Jorde UP, Fox MT, Möller BH, Penston J, McMurray JJV, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Cleland JGF, and Freemantle N

Published
2003
Full Text
View/download PDF

42. The RITA 3 trial.

Author

Pechlaner C, Wiedermann CJ, Melandri G, Möller BH, Dronfield MW, Morice AH, Fox KAA, Poole-Wilson PA, Henderson RA, Berry C, Balachandran KP, and Oldroyd KG

Published
2002
Full Text
View/download PDF

49. On the Bioisosteric Potential of Diazines:  Diazine Analogues of the Combined Thromboxane A<INF>2</INF> Receptor Antagonist and Synthetase Inhibitor Ridogrel

Author

Heinisch, G., Holzer, W., Kunz, F., Langer, T., Lukavsky, P., Pechlaner, C., and Weissenberger, H.

Abstract

In this SAR study the bioisosteric potential of diazines in the field of combined antithrombotic thromboxane A2 synthetase inhibitors and receptor antagonists was investigated. In this context, two series of (E)- and (Z)-ω-[[(aryldiazinylmethylene)amino]oxy]alkanoic acids were synthesized of which pentanoic acid derivatives with a 2-pyrazinyl, 4-pyridazinyl, or 5-pyrimidinyl group were found to exhibit this dual activity, while 4-pyrimidinyl as well as 3-pyridazinyl analogues showed only receptor antagonistic activity and 2-pyrimidinyl congeners were inactive. In the series of diazine analogues of Ridogrel (1), replacement of the 3-pyridyl group by a 2-pyrazinyl, 4-pyridazinyl, or 5-pyrimidinyl moiety led to compounds that inhibit thromboxane A2 synthetase in gel-filtered human platelets comparable to 1 (IC50 of 0.006, 0.016, and 0.039 μM, respectively, versus 0.007 μM). Radioligand-binding studies with [3H]SQ 29,548 in washed human platelets revealed that these diazine analogues block the thromboxane A2 receptor with an IC50 of 11, 6.0, and 1.5 μM, respectively. This compares well with the IC50 = 1.7 μM of 1. Finally, testing of inhibition of collagen-induced platelet aggregation in human platelet-rich plasma with 2-pyrazinyl, 4-pyridazinyl, or 5-pyrimidinyl congeners of Ridogrel indicated that these heteroaromatic moieties may serve as bioisosteric substitutes of a 3-pyridyl group in dual-acting antiplatelet agents.

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results